spacer
spacer

PDBsum entry 2hr0

Go to PDB code: 
protein ligands Protein-protein interface(s) links
Immune system PDB id
2hr0

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
641 a.a. *
907 a.a. *
Ligands
THC
Waters ×708
* Residue conservation analysis
Obsolete entry
PDB id:
2hr0
Name: Immune system
Title: Structure of complement c3b: insights into complement activation and regulation
Structure: Complement c3 beta chain. Chain: a. Fragment: residues 23-667. Complement c3 alpha' chain. Chain: b. Fragment: residues 749-1663
Source: Homo sapiens. Human. Organism_taxid: 9606. Organism_taxid: 9606
Biol. unit: Dimer (from PQS)
Resolution:
2.26Å     R-factor:   0.180     R-free:   0.194
Authors: A.Abdul Ajees,K.Gunasekaran,J.E.Volanakis,S.V.Narayana,G.J.Kotwal, H.M.Krishna Murthy
Key ref:
A.Abdul Ajees et al. (2006). The structure of complement C3b provides insights into complement activation and regulation. Nature, 444, 221-225. PubMed id: 17051152 DOI: 10.1038/nature05258
Date:
19-Jul-06     Release date:   31-Oct-06    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P01024  (CO3_HUMAN) -  Complement C3 from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1663 a.a.
641 a.a.*
Protein chain
Pfam   ArchSchema ?
P01024  (CO3_HUMAN) -  Complement C3 from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1663 a.a.
907 a.a.
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 

 
DOI no: 10.1038/nature05258 Nature 444:221-225 (2006)
PubMed id: 17051152  
 
 
The structure of complement C3b provides insights into complement activation and regulation.
A.Abdul Ajees, K.Gunasekaran, J.E.Volanakis, S.V.Narayana, G.J.Kotwal, H.M.Murthy.
 
  ABSTRACT  
 
The human complement system is an important component of innate immunity. Complement-derived products mediate functions contributing to pathogen killing and elimination. However, inappropriate activation of the system contributes to the pathogenesis of immunological and inflammatory diseases. Complement component 3 (C3) occupies a central position because of the manifold biological activities of its activation fragments, including the major fragment, C3b, which anchors the assembly of convertases effecting C3 and C5 activation. C3 is converted to C3b by proteolysis of its anaphylatoxin domain, by either of two C3 convertases. This activates a stable thioester bond, leading to the covalent attachment of C3b to cell-surface or protein-surface hydroxyl groups through transesterification. The cleavage and activation of C3 exposes binding sites for factors B, H and I, properdin, decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46), complement receptor 1 (CR1, CD35) and viral molecules such as vaccinia virus complement-control protein. C3b associates with these molecules in different configurations and forms complexes mediating the activation, amplification and regulation of the complement response. Structures of C3 and C3c, a fragment derived from the proteolysis of C3b, have revealed a domain configuration, including six macroglobulin domains (MG1-MG6; nomenclature follows ref. 5) arranged in a ring, termed the beta-ring. However, because neither C3 nor C3c is active in complement activation and regulation, questions about function can be answered only through direct observations on C3b. Here we present a structure of C3b that reveals a marked loss of secondary structure in the CUB (for 'complement C1r/C1s, Uegf, Bmp1') domain, which together with the resulting translocation of the thioester domain provides a molecular basis for conformational changes accompanying the conversion of C3 to C3b. The total conformational changes make many proposed ligand-binding sites more accessible and create a cavity that shields target peptide bonds from access by factor I. A covalently bound N-acetyl-l-threonine residue demonstrates the geometry of C3b attachment to surface hydroxyl groups.
 
  Selected figure(s)  
 
Figure 1.
Figure 1: C3, C3b and C3c. a, Top: diagrams showing domain movement on conversion to C3b. Red, C345C; yellow, MG7; grey, MG8; blue, ANA; purple, MG3; violet, CUBg and CUBf; green, TED. Bottom: schematic representation of the diagrams in the top row. The AcT-binding site is indicated by a white arrowhead. LNK, linker domain (residues 578–645). b, Largest changes. Left: positions of CUBg and CUBf in C3b (pink and blue), C3 (brown and cyan) and TED (red, C3; green, C3b); displacement of TED is visible. Right: top, changes in C345C (blue) and ANC (magenta); bottom, MG8 movement, from C3 (magenta) to C3b (blue).
Figure 4.
Figure 4: C3b inactivation. a, Electrostatic surface charge on C3b (left) and C3, contoured at 5 e Å^-2. The C3b surface is significantly more negative. b, Two Arg-Ser bonds and an Arg-Glu peptide bond that are cleaved in converting C3b to C3c are shown as sticks. Solvent-accessible surfaces of the -ring domains, coloured white, yellow, orange and beige, and TED (green) and CUBg and CUBf (magenta) are also shown. Sequestration of scissile bonds in a cavity that shields them from access to large proteases such as factor I is evident.
 
  The above figures are reprinted by permission from Macmillan Publishers Ltd: Nature (2006, 444, 221-225) copyright 2006.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
20666732 K.Li, J.Gor, and S.J.Perkins (2010).
Self-association and domain rearrangements between complement C3 and C3u provide insight into the activation mechanism of C3.
  Biochem J, 431, 63-72.  
20053731 P.K.Mallik, K.Nishikawa, A.J.Millis, and H.Shi (2010).
Commandeering a biological pathway using aptamer-derived molecular adaptors.
  Nucleic Acids Res, 38, e93.  
19218189 A.Yamaguchi, H.Takagawa, H.Iwakaji, S.Miyagawa, P.C.Wang, and N.Ishii (2009).
Construction of the plasmid, expression by Chinese hamster ovary cell, purification and characterization of the first three short consensus repeat modules of human complement receptor type 1.
  J Biochem, 145, 533-542.  
20033014 B.Borrell (2009).
Fraud rocks protein community.
  Nature, 462, 970.  
19219532 B.H.Lee, M.A.Tudares, and C.Q.Nguyen (2009).
Sjögren's syndrome: an old tale with a new twist.
  Arch Immunol Ther Exp (Warsz), 57, 57-66.  
19323824 R.Haque, T.M.Umstead, W.M.Freeman, J.Floros, and D.S.Phelps (2009).
The impact of surfactant protein-A on ozone-induced changes in the mouse bronchoalveolar lavage proteome.
  Proteome Sci, 7, 12.  
18456336 M.C.Schuster, D.Ricklin, K.Papp, K.S.Molnar, S.J.Coales, Y.Hamuro, G.Sfyroera, H.Chen, M.S.Winters, and J.D.Lambris (2008).
Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry.
  Mol Immunol, 45, 3142-3151.  
18697741 N.Doan, and P.G.Gettins (2008).
{alpha}-Macroglobulins Are Present in Some Gram-negative Bacteria: CHARACTERIZATION OF THE {alpha}2-MACROGLOBULIN FROM ESCHERICHIA COLI.
  J Biol Chem, 283, 28747-28756.  
18064050 P.Gros, F.J.Milder, and B.J.Janssen (2008).
Complement driven by conformational changes.
  Nat Rev Immunol, 8, 48-58.  
18677279 T.Karosi, A.Szalmás, P.Csomor, J.Kónya, M.Petkó, and I.Sziklai (2008).
Disease-associated novel CD46 splicing variants and pathologic bone remodeling in otosclerosis.
  Laryngoscope, 118, 1669-1676.  
17467263 A.DeWan, M.B.Bracken, and J.Hoh (2007).
Two genetic pathways for age-related macular degeneration.
  Curr Opin Genet Dev, 17, 228-233.  
17687277 B.J.Janssen, R.J.Read, A.T.Brünger, and P.Gros (2007).
Crystallography: crystallographic evidence for deviating C3b structure.
  Nature, 448, E1.  
  17675493 C.Q.Nguyen, H.Kim, J.G.Cornelius, and A.B.Peck (2007).
Development of Sjogren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3.
  J Immunol, 179, 2318-2329.  
17590164 M.van Lookeren Campagne, C.Wiesmann, and E.J.Brown (2007).
Macrophage complement receptors and pathogen clearance.
  Cell Microbiol, 9, 2095-2102.  
17445829 P.Roversi, O.Lissina, S.Johnson, N.Ahmat, G.C.Paesen, K.Ploss, W.Boland, M.A.Nunn, and S.M.Lea (2007).
The structure of OMCI, a novel lipocalin inhibitor of the complement system.
  J Mol Biol, 369, 784-793.
PDB codes: 2cm4 2cm9
17606907 R.H.Baxter, C.I.Chang, Y.Chelliah, S.Blandin, E.A.Levashina, and J.Deisenhofer (2007).
Structural basis for conserved complement factor-like function in the antimalarial protein TEP1.
  Proc Natl Acad Sci U S A, 104, 11615-11620.
PDB code: 2pn5
17989688 R.P.Rother, S.A.Rollins, C.F.Mojcik, R.A.Brodsky, and L.Bell (2007).
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
  Nat Biotechnol, 25, 1256-1264.  
17051146 M.Carroll (2006).
Immunology: exposure of an executioner.
  Nature, 444, 159-160.  
17172439 N.Nishida, T.Walz, and T.A.Springer (2006).
Structural transitions of complement component C3 and its activation products.
  Proc Natl Acad Sci U S A, 103, 19737-19742.  
17687278 , (0).
  , (), 0.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB codes are shown on the right.

 

spacer

spacer